{
    "clinical_study": {
        "@rank": "62055", 
        "arm_group": [
            {
                "arm_group_label": "RYGB with matched hypocaloric diet", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Hypocaloric Diet", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The focus of this proposal is to define the mechanism by which bariatric surgery acutely\n      improves glucose homeostasis.  Our central hypothesis is that drastically reduced caloric\n      intake early after Roux-en-Y Gastric Bypass (RYGB) improves the pro-inflammatory profile of\n      macrophages, which in turn improves insulin sensitivity and glucose homeostasis."
        }, 
        "brief_title": "Bariatric Surgery And Adipose Inflammation Dysfunction and Type 2 Diabetes Mellitus", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Type 2 Diabetes Mellitus", 
            "Insulin Resistance"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Insulin Resistance"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria::\n\n          1. Candidate for RYGB gastric bypass with insurance approval.\n\n          2. Willing to accept randomization to either immediate surgery, or delayed surgery after\n             diet study.\n\n          3. Willing to undergo two sessions of testing before, and ten days after surgery (or\n             initiation of dietary intervention).\n\n          4. BMI 35-45kg/m2\n\n          5. Pre-diabetes (ADA criteria) or T2DM with HbA1c< 8%.\n\n        Exclusion criteria:\n\n          1. T1DM.\n\n          2. Serious illness such as cancer, active chronic infection, cardiovascular disease\n             greater that New York Heart Association class 2, chronic renal failure, chronic lung\n             disease.\n\n          3. Inflammatory or celiac intestinal disease.\n\n          4. Untreated thyroid disease.\n\n          5. Serious psychiatric disease.\n\n          6. Excessive alcohol use.\n\n          7. Illicit drug use. -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01882036", 
            "org_study_id": "0908M70742"
        }, 
        "intervention": [
            {
                "arm_group_label": "RYGB with matched hypocaloric diet", 
                "description": "Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days", 
                "intervention_name": "Roux en Y Gastric Bypass", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Hypocaloric Diet", 
                "description": "Hypocaloric liquid diet for 10 days", 
                "intervention_name": "Hypocaloric diet", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 17, 2013", 
        "location": {
            "contact": {
                "email": "jschone1@fairview.org", 
                "last_name": "Joyce L Schone, RD", 
                "phone": "612-273-4860"
            }, 
            "contact_backup": {
                "email": "willi004@umn.edu", 
                "last_name": "Stanley E E. Williams, PhD", 
                "phone": "612 6253265"
            }, 
            "facility": {
                "address": {
                    "city": "Minneapolis", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55455"
                }, 
                "name": "University of Minnesota"
            }, 
            "investigator": {
                "last_name": "Sayeed Ikramuddin, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Effects of Roux-en-Y Gastric Bypass on Mitochondrial Dysfunction and Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "email": "jschone1@fairview.org", 
            "last_name": "JOYCE L SCHONE, RD", 
            "phone": "612-273-4860"
        }, 
        "overall_contact_backup": {
            "email": "willi004@umn.edu", 
            "last_name": "Stanley E E. Williams, PhD", 
            "phone": "612 6253265"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Measure homeostasis model assessment i.e. estimated change in insulin resistance (HOMA-IR) index", 
            "safety_issue": "No", 
            "time_frame": "Seven days before and 10 days following RYGB or hypocaloric diet similar to RYGB patients"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01882036"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Minnesota - Clinical and Translational Science Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "American Diabetes Association", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Minnesota - Clinical and Translational Science Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}